ANL
What one share of Adlai Nortye holds
Pharmaceutical Preparations
We are a global clinical-stage company at the forefront of discovering and developing innovative cancer therapies. Leveraging our dual R&D presence in the U.S. and China, we are building a robust pipeline of drug candidates focused on two key areas where we believe we can make a significant difference.
Adlai Nortye’s numbers from its SEC filings, divided by its shares. Results cover the latest fiscal year to 2025-12-31; the balance sheet is as of 2025-12-31.
| Sales | $0.16 |
|---|---|
| Profit | −$1.11 |
| Capex (buildings and equipment) | $0.01 |
| Free cash flow | −$1.05 |
| Cash and investments | $0.25 |
| Debt | $0.82 |
| Book value | −$0.26 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2021 | $5.39 | −$6.68 | $0.12 | −$0.48 | — | −$21.87 |
| 2022 | — | −$6.93 | $0.15 | −$5.24 | — | −$17.90 |
| 2023 | $0.35 | −$7.56 | $0.01 | −$3.94 | — | $5.19 |
| 2024 | — | −$1.62 | $0.01 | −$1.63 | — | $0.80 |
| 2025 | $0.16 | −$1.11 | $0.01 | −$1.05 | — | −$0.26 |